Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.59 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24543121 | 0.95 | HRH3 (0.74) | HRH3SMN1; SMN2HIF1AEPAS1NPC1 | |
| SCHEMBL19241878 | 0.94 | HRH3 (0.59) | HRH3SMN1; SMN2HIF1AEPAS1NPC1 | |
| SCHEMBL15467001 | 0.84 | HRH3 (0.87) | HRH3SMN1; SMN2HIF1AEPAS1NOS3 | |
| SCHEMBL3277960 | 0.84 | HRH3 (0.67) | HRH3SMN1; SMN2HIF1AEPAS1NPC1 | |
| SCHEMBL18403966 | 0.83 | NCF1 (0.67) | HRH3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14980018 | 0.83 | SIGMAR1 (0.55) | HRH3HTTMEN1KMT2A | |
| SCHEMBL15677807 | 0.83 | HIF1A (0.64) | HRH3SMN1; SMN2HIF1AEPAS1NPC1 | |
| SCHEMBL14313879 | 0.82 | NCF1 (0.71) | HRH3SMN1; SMN2HIF1AEPAS1HTT | |
| SCHEMBL22889633 | 0.82 | HRH3 (0.65) | HRH3SMN1; SMN2HIF1AEPAS1NPC1 | |
| SCHEMBL12038517 | 0.81 | HRH3 (0.69) | HRH3SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140851-B1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2004-09-01 | — | — | EP | claimed |
| CN-1132818-C | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN CO. (US) | 2003-12-31 | — | — | CN | claimed |
| CN-1332729-A | 4-oxo-1,4-dihybro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UP JOHN CO (US) | 2002-01-23 | — | — | CN | claimed |
| EP-1140851-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| US-6248736-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | claimed |
| WO-2000040563-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-114075180-B | Immunomodulatory compounds and anti-tumor applications thereof | 上海科技大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-112601751-B | Fused thiophene compounds | 拜欧斯瑞克斯公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112601751-A | Fused thiophene compounds | 拜欧斯瑞克斯公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-110317202-A | Cyanopyrrole and heteroaryl analog derivative, preparation method and its application in medicine | 江苏恒瑞医药股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | disclosed |
| EP-2681247-B1 | Polymers containing an acid group and their use as a catalyst | CADENA BIO INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-1211251-A1 | CHROMONE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-6355672-B1 | BONE DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| CN-1332729-A | 4-oxo-1,4-dihybro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UP JOHN CO (US) | 2002-01-23 | — | — | CN | disclosed |
| EP-1140851-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248736-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
| EP-1103552-A1 | BENZOTHIEPIN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000040563-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | HRH3 655/4885SMN1; SMN2 2232/4885HIF1A 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.